Birchview Capital’s Foghorn Therapeutics FHTX Stock Holding History

Birchview Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.35M	Hold	281,730	–	–	0.77%	35
2025 Q4	$1.52M	Hold	281,730	–	–	0.89%	30
2025 Q3	$1.38M	Sell	281,730 -29,200	-9%	-$155K	1.04%	25
2025 Q2	$1.46M	Hold	310,930	–	–	1.45%	20
2025 Q1	$1.13M	Hold	310,930	–	–	0.99%	23
2024 Q4	$1.47M	Sell	310,930 -10,000	-3%	-$72.8K	1.19%	21
2024 Q3	$2.99M	Hold	320,930	–	–	2.59%	11
2024 Q2	$1.85M	Hold	320,930	–	–	1.71%	16
2024 Q1	$2.15M	Hold	320,930	–	–	1.76%	14
2023 Q4	$2.07M	Buy	320,930 +56,087	+21%	+$242K	1.62%	13
2023 Q3	$1.32M	Hold	264,843	–	–	1.13%	17
2023 Q2	$1.86M	Hold	264,843	–	–	1.4%	14
2023 Q1	$1.64M	Hold	264,843	–	–	1.29%	13
2022 Q4	$1.69M	Hold	264,843	–	–	1.19%	15
2022 Q3	$2.27M	Sell	264,843 -20,000	-7%	-$257K	1.6%	12
2022 Q2	$3.87M	Sell	284,843 -9,300	-3%	-$120K	2.82%	5
2022 Q1	$4.48M	Sell	294,143 -20,000	-6%	-$274K	3.23%	6
2021 Q4	$7.18M	Hold	314,143	–	–	4.63%	6
2021 Q3	$4.38M	Hold	314,143	–	–	2.98%	6
2021 Q2	$3.35M	Hold	314,143	–	–	2.01%	9
2021 Q1	$4.14M	Hold	314,143	–	–	2.46%	7
2020 Q4	$6.37M	Buy	+314,143	New	+$6.02M	3.67%	6

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Birchview Capital's FHTX Position: Q1 2026 in Review

Birchview Capital held its Foghorn Therapeutics (FHTX) position steady in Q1 2026 at 281,730 shares worth $1.35M. The position accounts for 0.77% of the portfolio, ranked #35.

Birchview Capital first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.18M in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

Birchview Capital held 281,730 shares of Foghorn Therapeutics worth $1.35M as of Q1 2026.
Birchview Capital left its Foghorn Therapeutics share count unchanged in Q1 2026.
Foghorn Therapeutics made up 0.77% of Birchview Capital's portfolio in Q1 2026, its #35 holding.
Birchview Capital first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
Birchview Capital's Foghorn Therapeutics position peaked at $7.18M in Q4 2021.
105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.